Klaus Beiske

MedicineImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 2 papers. Top paper: “Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting”.

Early‐phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

Cancer(2022)10.1002/cncr.34445

N/A

0DataRank · unranked

14 citations

Judith G. Villablanca, Barbara Hero, Brian H. Kushner, Keith Wheatley, Klaus Beiske +9 more

Evaluation of clinical parameters and biomarkers in older, untreated mantle cell lymphoma patients receiving bendamustine–rituximab

British Journal of Haematology(2023)10.1111/bjh.19153

N/A

0DataRank · unranked

5 citations

Allison Rosenthal, Ryan S. Robetorye, Raphael Mwangi, Matthew J. Maurer, Diego Villa +20 more